Results 271 to 280 of about 263,791 (359)

It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening. [PDF]

Cancer Epidemiol Biomarkers Prev
Brenner AT, Odebunmi OO, Waters AR, Wangen M, Marciniak MW, Ferrari RM, Wheeler SB, Shah PD.   +7 more
europepmc   +1 more source

Outcomes evaluation of a pharmacist discharge medication teaching service

, 1998
Kathi Salmon Lucas
openalex   +1 more source

Seattle-King County Pharmaceutical Society and Greater Seattle Retail Drug Association, Inc. and Pharmacists and Retail Drug Stores Employees Union, Local 330 (1968) [PDF]

, 1968

core   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Effectiveness of the kakaritsuke-yakuzaishi (family pharmacist) system for underage individuals in Japan: a cohort study using a health insurance claims database. [PDF]

BMC Health Serv Res
Iketani R.
europepmc   +1 more source

Prescriptions for Excellence in Health Care Spring 2011 Download PDF [PDF]

, 2011

core   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Pharmaceutical Care Services in Community Pharmacies: An Umbrella Review of Global Evidence with Insights from Polish and Spanish Practices. [PDF]

Integr Pharm Res Pract
Żuk A, Machuca M.
europepmc   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Optimism Model by a Cardiology Pharmacist in Breaking Bad News Among Patients with CTRCD and its Impact on Outcomes. [PDF]

Glob Heart
Yaseen IF, Farhan HA.
europepmc   +1 more source